<doc>
  <docmeta id="113s2134is">
    <bill congress="113" type="s" number="2134" version="is"/>
    <revision size="4662" annotations="0" status="complete" id="5" commit-time="2014-03-21T19:58:06Z" committer="mbohmer" doc="113s2134is/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 S2134 IS: Act to Ban Zohydro</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. Senate</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-03-13</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>S. 2134</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20140313">March 13, 2014</action-date>
			<action-desc>
        <sponsor name-id="S338">Mr. Manchin</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To withdraw approval for the drug Zohydro ER and prohibit the Food and Drug Administration from
			 approving such drug unless it is reformulated to prevent abuse. </official-title>
	</form>
	<legis-body id="H1068DE95BDA94E6BAA52DA67D3E31761" style="OLC">
		<section id="H1BC2D7D3AC3347729406876EF745ACED" section-type="section-one">
			<enum>1.</enum>
			<header>Short title</header>
			<text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Act to Ban Zohydro" proposed="true">Act to Ban Zohydro</cato:entity-ref>
          </short-title>
        </quote>.</text>
		</section>
    <section id="H4B74B8AFBAB4407786E3B7E135CDB43C">
			<enum>2.</enum>
			<header>Findings</header>
			<text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds as follows:</text>
			<paragraph id="H57D0A956B2E849C39749AF36763CCB5A">
				<enum>(1)</enum>
				<text display-inline="yes-display-inline">The drug Zohydro ER is a high-dose hydrocone-only opioid narcotic painkiller listed in schedule II
			 of <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Controlled Substances Act/s:202/ss:c">section 202(c) of the Controlled Substances Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/812">
            <cato:entity-ref entity-type="uscode" value="usc/21/812/c">21 U.S.C. 812(c)</cato:entity-ref>
          </external-xref>)</cato:entity>.</text>
			</paragraph>
      <paragraph id="H84333C24DE35461896F9C12C9B0B5574">
				<enum>(2)</enum>
				<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> Anesthetic and Analgesic Drug Products Advisory Committee report
			 cited available
			 dosages of Zohydro ER that, according to health care and substance abuse
			 professionals, have up to 10 times more hydrocodone than any hydrocodone
			 painkiller currently on the market.</text>
			</paragraph>
      <paragraph id="HBC139636E194437B9FFED7A18DFD0C1F">
				<enum>(3)</enum>
				<text>Zohydro ER is manufactured without an abuse deterrent formulation.</text>
			</paragraph>
      <paragraph id="HB4685675C919466BB22361BFB025A72D">
				<enum>(4)</enum>
				<text>Zohydroâ€™s time-released effect, an important element of its pharmaceutical use, is easily negated
			 by abusers to achieve a heroin-like effect.</text>
			</paragraph>
      <paragraph id="HAB8D235ED267480AA34C8495A20C6051">
				<enum>(5)</enum>
				<text>The Anesthetic and Analgesic Drug Products Advisory Committee concluded that, if approved and
			 marketed, Zohydro ER
			 will be abused, possibly at a rate greater than that of currently
			 available hydrocodone combination products.</text>
			</paragraph>
      <paragraph id="H6A6E97092E834960B2A3FCB6C6DB6A84">
				<enum>(6)</enum>
				<text>The Anesthetic and Analgesic Drug Products Advisory Committee voted 11 to 2 against approval of
			 Zohydro ER, citing the high possibility for addiction.</text>
			</paragraph>
      <paragraph id="H84B73D50F81147DA90F5061E04388557">
				<enum>(7)</enum>
				<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> approved Zohydro ER without an abuse deterrent formulation despite
			 the fact that the Anesthetic and Analgesic Drug Products Advisory
			 Committee voted 11 to 2 against doing so.</text>
			</paragraph>
      <paragraph id="H363E0F61678545FAB0CE7ADE17EF478F">
				<enum>(8)</enum>
				<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has acknowledged that the widespread abuse of opioid drugs across
			 the country has reached epidemic proportions in some parts of the country.</text>
			</paragraph>
      <paragraph id="H58537A878CB1419F9E8F26293BFD8BFC">
				<enum>(9)</enum>
				<text>According to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers for Disease Control and Prevention</cato:entity-ref>, deaths connected to prescription
			 opioids have more than quadrupled in the United States, from 4,030 deaths
			 involving the painkillers in 1999 to 16,651 deaths in 2010.</text>
			</paragraph>
      <paragraph id="H135BA662294C4B1DAE8D3BA978CB6D58">
				<enum>(10)</enum>
				<text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers for Disease Control and Prevention</cato:entity-ref> has identified reducing deaths attributable to
			 prescription painkiller abuse and overdose as a top health priority for
			 2014.</text>
			</paragraph>
      <paragraph id="H59B228C40A3E407A80BC558D28B7B32B">
				<enum>(11)</enum>
				<text>Attorneys General from 28 States have asked the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> to reconsider its
			 approval of Zohydro ER.</text>
			</paragraph>
      <paragraph id="HD94CB7D988EC4D7E865A1F5B4049B896">
				<enum>(12)</enum>
				<text>Health care professionals, addiction treatment providers, and community-based drug and alcohol
			 prevention programs are groups opposed to the approval of Zohydro ER.</text>
			</paragraph>
      <paragraph id="HBEA3EF1E1CA5415598386CC23DDB4DBF">
				<enum>(13)</enum>
				<text>The burdens of Zohydro ER to the public health outweigh its potential therapeutic benefits. Given
			 that alternative pain medicines and methods are widely available, approval
			 of Zohydro ER should be withdrawn until such time that there is available
			 a Food and Drug Administration-approved abuse deterrent formulation.</text>
			</paragraph>
    </section>
    <section id="H39CB88465A744934B069C267CF69E860">
			<enum>3.</enum>
			<header>Withdrawal of approval of drug Zohydro ER</header>
			<subsection id="H98693F7455CD4FA29C87C4004C7D741C">
				<enum>(a)</enum>
				<header>Withdrawal of approval</header>
				<text display-inline="yes-display-inline">Effective beginning on the day that is 45 days after the date of enactment of this Act, approval of
			 the application with respect to pure hydrocodone bitartrate
			 extended-release capsules (marketed as the drug Zohydro ER) under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">section
			 505(c) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
            <cato:entity-ref entity-type="uscode" value="usc/21/355/c">21 U.S.C. 355(c)</cato:entity-ref>
          </external-xref>)</cato:entity> is
			 deemed to have been withdrawn under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:e">section 505(e) of such Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/e">21 U.S.C.
			 355(e)</cato:entity-ref>)</cato:entity>.</text>
			</subsection>
      <subsection id="H4467A50BAFF34BD68D93A27F0FAAD478">
				<enum>(b)</enum>
				<header>No approval of any formulation that is not abuse deterrent</header>
				<text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref> shall not approve any application under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505 of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
            <cato:entity-ref entity-type="uscode" value="usc/21/355">21 U.S.C. 355</cato:entity-ref>
          </external-xref>)</cato:entity> for pure hydrocodone
			 bitartrate extended-release capsules unless such drug is formulated to
			 prevent abuse.</text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>